<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153125</url>
  </required_header>
  <id_info>
    <org_study_id>0405-13-TLV</org_study_id>
    <nct_id>NCT02153125</nct_id>
  </id_info>
  <brief_title>Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the efficacy and safety in treating patients with
      chronic central serous chorioretinopathy with the drug eplerenone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The goal of the study is to examine the short-term effects and safety of eplerenone, a
           systemic anti-aldosterone medication, in a group of patients with central serous
           chorioretinopathy (CSCR).

        -  There is currently no standard treatment or therapy for chronic CSCR, a potentially
           debilitating eye disease.

        -  There is evidence that high blood serum corticosteroid levels can cause or worsen CSCR

        -  Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and
           anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that
           decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR

        -  The study's aim is to evaluate a standardized dose of eplerenone in a controlled
           prospective fashion for chronic CSCR.

        -  The study consists of taking a standard dose of eplerenone, 25mg once daily for a week,
           followed by 50mg once daily, for a total of 3 months

        -  Patients will be monitored for efficacy and side effects from the beginning of treatment
           and for 6 months
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of at least 10% in subretinal fluid thickness as measured by optical coherence tomography (OCT)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg eplerenone given daily for a week, followed by 50mg given for a total of 3 months since commencement of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic central serous chorioretinopathy (CSCR): Previous diagnosis of CSCR,
             persistent subretinal fluid on OCT for more than 4 months after initial presentation
             to the eye clinic

        Exclusion Criteria:

          -  Other retinal disease

          -  Choroidal neovascularization

          -  Diabetes

          -  A history of uveitis

          -  Ocular surgery in the prior 3 months

          -  Allergy to fluorescein or indocyanine green

          -  Pregnancy, lactation or female patients in fertility age not treated with
             contraceptive pills

          -  Creatinine clearance &lt; 50 ml/min

          -  Hyperkalemia &gt; 5 mmol/l

          -  Patients treated with drugs deactivated by cytochrome P450 3A4 (CYP3A4)

          -  Serum creatinine &gt; 2 mg/dl in men or &gt; 1.8 mg/dl in women

          -  Treatment with potassium sparing agents or potassium

          -  Treatment with Angiotensin converting enzyme (ACE)/angiotensin II receptor blocker
             (ARB) inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michaella Goldstein, MD</last_name>
    <phone>97236974361</phone>
    <email>michgold@netvision.net.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel Aviv Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michaella Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roy Schwartz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Martinez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zohar Wilner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shiri Shulman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oded Ohana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shay Keren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dafna Goldenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meira Neuderfer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chanan Guzner-Gur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Nutman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anat Loewenstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012 Jul;122(7):2672-9. doi: 10.1172/JCI61427. Epub 2012 Jun 11.</citation>
    <PMID>22684104</PMID>
  </reference>
  <reference>
    <citation>Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 2010 Dec;24(12):1743-56. doi: 10.1038/eye.2010.130. Epub 2010 Oct 8. Review.</citation>
    <PMID>20930852</PMID>
  </reference>
  <reference>
    <citation>Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008 Oct;115(10):1756-65. doi: 10.1016/j.ophtha.2008.04.014. Epub 2008 Jun 5.</citation>
    <PMID>18538401</PMID>
  </reference>
  <reference>
    <citation>Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010 Feb;149(2):307-315.e2. doi: 10.1016/j.ajo.2009.08.026. Epub 2009 Nov 6.</citation>
    <PMID>19896635</PMID>
  </reference>
  <reference>
    <citation>Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983 Apr;95(4):457-66.</citation>
    <PMID>6682293</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>Michaella Goldstein</investigator_full_name>
    <investigator_title>Deputy Head Department of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

